Symmetric Dimethylarginine in Cats with Hypertrophic Cardiomyopathy and Diabetes Mellitus

Background

Symmetric dimethylarginine (SDMA) has been increasingly used as a marker of early chronic kidney disease (CKD) in cats, but little is known about the influence of comorbidities on SDMA in this species.

Hypothesis

Hypertrophic cardiomyopathy (HCM) and diabetes mellitus (DM), independently of CKD, are associated with changes in serum SDMA.

Animals

Ninety‐four cats (17 with CKD, 40 with HCM, 17 with DM, and 20 healthy controls).

Methods

Case‐control study. Clinical examination, echocardiography, ECG, blood pressure, CBC, biochemistry, thyroxine, and SDMA measurement were performed. Urinalysis was performed in controls and cats with CKD and DM. Analysis of variance was used to compare overall differences in the log‐transformed SDMA data among groups. A random forest algorithm was applied to explore which clinical and other factors influenced serum SDMA.

Results

Median (range) serum SDMA for the renal group (positive control) was 19 (10–93) μg/dL, whereas for the control group (negative control), it was 10 (5–15) μg/dL. For the cardiac and diabetic groups, serum SDMA was 9 (4–24) μg/dL and 7 (3–11) μg/dL, respectively. The renal group had significantly higher SDMA concentrations and the diabetic group significantly lower SDMA concentrations compared to all other groups.

Conclusions and Clinical Importance

Serum SDMA concentrations in cats with HCM were not significantly different from those of healthy control cats. Cats with DM, however, had significantly lower SDMA concentrations than controls, a finding that needs further investigation and should be kept in mind when evaluating renal function of cats with this endocrinopathy.     

一例犬肝脏肿瘤并发糖尿病诊断与分析

2018年10月,宠物医院接到一只10岁龄患犬,为肝脏肿瘤并发糖尿病病例,对其进行体格检查和实验室检查,实验室检查的项目有B超、血常规检测、血生化检测和血气分析检测。诊断该犬为肝脏肿瘤并发糖尿病。用补液、降糖的原则对该犬的糖尿病进行治疗,肝脏肿瘤因宠物主人意愿宠物接受保守治疗。患犬经住院治疗病情稳定后出院。     

Remission of Diabetes Mellitus in Cats with Diabetic Ketoacidosis

Background: Diabetic ketoacidosis (DKA) has long been considered a key clinical feature of type‐1 diabetes mellitus (DM) in humans although. An increasing number of cases of ketoacidosis have been reported in people with type‐2 DM. Hypothesis/Objectives: Cats initially diagnosed with DKA can achieve remission from diabetes. Cats with DKA and diabetic remission are more likely to have been administered glucocorticoids before diagnosis. Animals: Twelve cats with DKA and 7 cats with uncomplicated DM. Methods: Retrospective case review. Medical records of cats presenting with DKA or DM were evaluated. Diabetic remission was defined as being clinically unremarkable for at least 1 month after insulin withdrawal. The cats were assigned to 1 of 3 groups: (1) cats with DKA and diabetic remission; (2) cats with DKA without diabetic remission; and (3) cats with DM and diabetic remission. Results: Seven cats with DKA had remission from diabetes. These cats had significantly higher concentrations of leukocytes and segmented neutrophils, and significantly lower concentrations of eosinophils in blood and had pancreatic disease more often than did cats with uncomplicated DM and diabetic remission. With regard to pretreatment, 3/7 cats in group 1, 1/5 cats in group 2, and 1/7 cats in group 3 had been treated with glucocorticoids. Conclusions and Clinical Importance: Remission of DM in cats presenting with DKA is possible. Cats with DKA and remission have more components of a stress leucogram, pancreatic disease, and seemed to be treated more often with glucocorticoids than cats with uncomplicated DM and diabetic remission.     

蜂巢中总黄酮测试方法的探讨

用乙醇作溶剂浸渍蜂巢,浸渍时间分别为1～15d。用751G分光光度计,在波长510nm处,测定其滤液中的总黄酮含量,分析蜂巢浸渍液中总黄酮的变化规律。试验表明蜂巢浸渍7天测定其滤液总黄酮含量为最佳。     

花粉、蜂胶对糖尿病SD大鼠的影响

以花粉、蜂胶水提液、蜂胶醇提液为材料，测定和比较了花粉和不同提取方法的蜂胶对糖尿病SD大鼠血糖的影响以及给药4周后对果糖胺、甘油三酯、总胆固醇、肌酐、丙二醛、白蛋白、总蛋白的影响，以及各组动物的肾重／体重。结果表明。花粉、蜂胶能在一定时间内控制血糖；花粉对肾脏具有一定的保护作用。花粉、蜂胶均能降低果糖胺、甘油三酯、总胆固醇、肌酐、丙二醛水平；减少总蛋白，白蛋白的消耗，说明花粉、蜂胶能改善糖尿病大鼠体内糖、蛋白质、脂肪代谢，减少糖尿病并发症的危害。     

蜂胶对糖尿病大鼠血糖的影响

将复制糖尿病模型的 72只SD大鼠随机分为模型组 ,蜂胶水提液低剂量组、高剂量组 ,蜂胶醇提液低剂量组、高剂量组和阳性对照组 (拜糖苹 ) ,另取 12只为正常组。除正常组和模型组外 ,各组分别给予不同的试验药物。给药过程中 ,每周取血一次 ,测空腹血糖 ,给药 7周后 ,取血测定空腹血糖和果糖胺。试验结果表明 ,蜂胶水提液和醇提液均能控制糖尿病大鼠空腹血糖的升高 ,并且随着时间的延长效果越来越明显。     

Cardiac Troponins in Dogs and Cats

Cardiac troponins are sensitive and specific markers of myocardial injury. The troponin concentration can be thought of as a quantitative measure of the degree of injury sustained by the heart, however, it provides no information on the cause of injury or the mechanism of troponin release. Conventionally, the cardiac troponins have been used for diagnosis of acute myocardial infarction in humans and have become the gold standard biomarkers for this indication. They have become increasingly recognized as an objective measure of cardiomyocyte status in both cardiac and noncardiac disease, supplying additional information to that provided by echocardiography and ECG. Injury to cardiomyocytes can occur through a variety of mechanisms with subsequent release of troponins. Independent of the underlying disease or the mechanism of troponin release, the presence of myocardial injury is associated with an increased risk of death. As increasingly sensitive assays are introduced, the frequent occurrence of myocardial injury is becoming apparent, and our understanding of its causes and importance is constantly evolving. Presently troponins are valuable for detecting a subgroup of patients with higher risk of death. Future research is needed to clarify whether troponins can serve as monitoring tools guiding treatment, whether administering more aggressive treatment to patients with evidence of myocardial injury is beneficial, and whether normalizing of troponin concentrations in patients presenting with evidence of myocardial injury is associated with reduced risk of death.     

Evaluation of IGF-1 levels in cats with transient and permanent diabetes mellitus

It was investigated if IGF-1 levels in cats which experience diabetic remission (i.e. transient diabetes mellitus) differ from those in cats with permanent disease. Thirteen of 32 diabetic cats showed remission within 16 weeks after initiating insulin therapy, 19 cats continued to need insulin therapy. IGF-1 concentrations were measured before (t(0)), 1-3 (t(1)) and 4-8 (t(2)) weeks after initiating insulin therapy. No difference in IGF-1 levels was found between cats with transient and permanent diabetes at any point in time. In both groups of cats IGF-1 concentrations were significantly lower compared to those of controls before insulin administration. After starting insulin therapy IGF-1 increased significantly in both groups. In cats with transient diabetes IGF-1 levels were not different from controls already at t(1), whereas in cats with permanent diabetes it took until t(2). Although IGF-1 levels seem to normalize faster in cats with transient diabetes mellitus, measurement is not helpful to predict the course of the disease.